Literature DB >> 26189996

Maintenance therapy of gastroesophageal reflux disease.

Akihito Nagahara1, Mariko Hojo2, Daisuke Asaoka2, Sumio Watanabe2.   

Abstract

The aims of treatment of gastroesophageal reflux disease (GERD) are to cure mucosal breaks, control symptoms, and prevent complications (e.g. stricture, Barrett's esophagus, and esophageal adenocarcinoma). Proton pump inhibitors (PPIs) are known to be the best drugs to cure esophagitis; however, a highrecurrence rate of about 80% was described after the completion of initial therapy. Regretfully, not so many physicians perform maintenance therapy in clinical practice. Histamine H2 receptor antagonists have an insufficient effect in maintenance therapy compared with PPIs; therefore, they could be prescribed for mild reflux esophagitis. Several clinical trials have been conducted to investigate the efficacy of continuous PPI administration maintenance therapy for GERD. Among these trials, recent large-scale studies showed that esomeprazole was equal to or superior to other kinds of PPIs. On the other hand, on-demand PPI studies have been conducted, mainly in patients with nonerosive reflux disease or uninvestigated GERD;however, this strategy was less effective than continuous therapy in many studies. Because on-demand therapy is less expensive, it is worth confirming this strategy in further studies. Studies of maintenance therapy with investigations conducted for as long a period as 5 years have described that PPI maintenance therapy could be considered as effective, safe, and well tolerated.

Entities:  

Keywords:  GERD; Maintenance therapy; On-demand therapy; Reflux esophagitis

Year:  2010        PMID: 26189996     DOI: 10.1007/s12328-010-0139-z

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  60 in total

1.  Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams.

Authors:  Kenneth R Devault; John F Johanson; David A Johnson; Sherry Liu; Mark B Sostek
Journal:  Clin Gastroenterol Hepatol       Date:  2006-05-06       Impact factor: 11.382

2.  Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease.

Authors:  F Pace; C Negrini; I Wiklund; C Rossi; V Savarino
Journal:  Aliment Pharmacol Ther       Date:  2005-08-15       Impact factor: 8.171

3.  Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH.

Authors:  N Shirai; T Furuta; Y Moriyama; H Okochi; K Kobayashi; M Takashima; F Xiao; K Kosuge; K Nakagawa; H Hanai; K Chiba; K Ohashi; T Ishizaki
Journal:  Aliment Pharmacol Ther       Date:  2001-12       Impact factor: 8.171

4.  Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice.

Authors:  T L Venables; R D Newland; A C Patel; J Hole; M B Copeman; M L Turbitt
Journal:  Scand J Gastroenterol       Date:  1997-07       Impact factor: 2.423

5.  The role of excessive esophageal acid exposure in patients with gastroesophageal reflux disease.

Authors:  Katsuhiko Iwakiri
Journal:  Clin J Gastroenterol       Date:  2009-12-05

6.  Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study.

Authors:  J Labenz; D Armstrong; K Lauritsen; P Katelaris; S Schmidt; K Schütze; G Wallner; H Juergens; H Preiksaitis; N Keeling; E Nauclér; J Adler; S Eklund
Journal:  Aliment Pharmacol Ther       Date:  2005-11-01       Impact factor: 8.171

Review 7.  Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease.

Authors:  Ronnie Fass
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

8.  Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study.

Authors:  H H Tsai; R Chapman; A Shepherd; D McKeith; M Anderson; D Vearer; S Duggan; J P Rosen
Journal:  Aliment Pharmacol Ther       Date:  2004-09-15       Impact factor: 8.171

9.  Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease.

Authors:  P Bytzer; A Blum; D De Herdt; D Dubois
Journal:  Aliment Pharmacol Ther       Date:  2004-07-15       Impact factor: 8.171

10.  Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine.

Authors:  Masaki Miyamoto; Ken Haruma; Masao Kuwabara; Makoto Nagano; Takeshi Okamoto; Mio Tanaka
Journal:  J Gastroenterol Hepatol       Date:  2007-05       Impact factor: 4.029

View more
  3 in total

1.  Difference in efficacy of proton pump inhibitor between new-onset and recurrent gastroesophageal reflux disease: Result from a study of on-demand versus continuous maintenance therapy in Japan.

Authors:  A Nagahara; D Asaoka; M Hojo; H Sasaki; Y Shimada; K Matsumoto; H Ueyama; T Shibuya; N Sakamoto; T Osada; S Watanabe
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

2.  A randomized prospective study comparing the efficacy of on-demand therapy versus continuous therapy for 6 months for long-term maintenance with omeprazole 20 mg in patients with gastroesophageal reflux disease in Japan.

Authors:  Akihito Nagahara; Mariko Hojo; Daisuke Asaoka; Hitoshi Sasaki; Sumio Watanabe
Journal:  Scand J Gastroenterol       Date:  2014-01-21       Impact factor: 2.423

3.  On-demand versus half-dose continuous therapy with esomeprazole for maintenance treatment of gastroesophageal reflux disease: A randomized comparative study.

Authors:  Joon Hyun Cho; Ji Yeon Koo; Kyeong Ok Kim; Si Hyung Lee; Byung Ik Jang; Tae Nyeun Kim
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.